Daewon Pharmaceutical Co (XKRX:003220) Net Income (Continuing Operations) : ₩6,032 Mil (TTM As of Mar. 2025)

View and export this data going back to 1999. Start your Free Trial

What is Daewon Pharmaceutical Co Net Income (Continuing Operations)?

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Daewon Pharmaceutical Co's Net Income (Continuing Operations) for the three months ended in Mar. 2025 was ₩4,917 Mil. Its Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Mar. 2025 was ₩6,032 Mil.

Daewon Pharmaceutical Co Net Income (Continuing Operations) Historical Data

The historical data trend for Daewon Pharmaceutical Co's Net Income (Continuing Operations) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Daewon Pharmaceutical Co Net Income (Continuing Operations) Chart

Daewon Pharmaceutical Co Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Net Income (Continuing Operations)

Get a 7-Day Free Trial

17,198.49

6,610.68

30,657.17

23,463.26

10,103.80

Daewon Pharmaceutical Co Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Net Income (Continuing Operations)	Get a 7-Day Free Trial															8,989.40	-2,269.61	5,639.80	-2,255.79	4,917.24

Daewon Pharmaceutical Co Net Income (Continuing Operations) Calculation

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period.

Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩6,032 Mil.

Daewon Pharmaceutical Co (XKRX:003220) Net Income (Continuing Operations) Explanation

Net Income (Continuing Operations) excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Daewon Pharmaceutical Co Net Income (Continuing Operations) Related Terms

Thank you for viewing the detailed overview of Daewon Pharmaceutical Co's Net Income (Continuing Operations) provided by GuruFocus.com. Please click on the following links to see related term pages.

Daewon Pharmaceutical Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Daewon Pharmaceutical Co Ltd (XKRX:003220) » Definitions » Net Income (Continuing Operations)

Traded in Other Exchanges

N/A

Address

229-3 Yongdap-dong, Seongdong-gu, Seoul, KOR, 133-850

Website

https://www.daewonpharm.com

Daewon Pharmaceutical Co Ltd is active in the healthcare sector in Korea. Its main business involves antipyretics, respiratory drugs, cardiovascular drugs, and neuromuscular drugs. It also produces a range of health foods such as multivitamins. The company operates on a global basis.

Daewon Pharmaceutical Co Headlines

No Headlines